Press release
Most promising radiopharmaceuticals on the market by 2024-2026
This new report covers 35 products along with the profile of the 27 companies developing these products, and aims to advice on the potential for investments, merger and acquisitions (M&A), technology and market development existing in this healthcare technology.
Detailed table of contents and sample pages available upon request at peg@medraysintell.com
Several new radiopharmaceuticals will enter the market in the coming years fueling the growth of the global Nuclear Medicine market which was valued at some US$ 4.5 billion in 2016 and is expected to reach US$ 26 billion in 2030, with radiotherapeutics to represent 60% of the nuclear medicine market by 2030 compared to 12% in 2016.
Most of the new products that are expected to reach the market by 2024-2026 will be labelled with Fluorine-18, Gallium-68 or Technetium-99m for the radiodiagnostics and with Lutetium-177 and Iodine-131 for the radiotherapeutic products.
This report is an excerpt of the full report entitled “Nuclear Medicine World Market Report & Directory Edition 2017” published in July 2017, and will be a real asset for the healthcare industry or for the financial community (investors, investment bankers and M&A professionals) to support their audit and to make informed decisions with unbiased and factual intelligence from experts.
About MEDraysintell
MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy.
We offer the most comprehensive set of reports and directories, with over 2,100 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts. We are proud to support numerous companies globally, helping them better understand the markets, competitive environment as well as the potential of merger and acquisitions (M&A) and technology development. We have repeat satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories.
MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. It combines over 40 years of experience in radiation healthcare. www.medraysintell.com
MEDraysintell
Chemin du Cyclotron 6
1348 Louvain-la-Neuve, Belgium
Paul-Emmanuel Goethals
peg@medraysintell.com
+32 491 080 968
www.medraysintell.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Most promising radiopharmaceuticals on the market by 2024-2026 here
News-ID: 926274 • Views: …
More Releases for MEDraysintell
Brachytherapy Market 2020-2026 Observational Studies || Leading Players - VARIAN …
Global brachytherapy marketis estimated to rise at a substantial CAGR of 8.7% in the forecast period of 2019 to 2026. The imminent market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026. The growth of the market can be attributed to the rise in government initiatives.
Get Exclusive Sample Copy of This Report Here https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-brachytherapy-market&raksh
Some of the major…
Impulse from radiotherapeutics confirms accelerated growth of nuclear medicine
MEDraysintell releases its new Nuclear Medicine World Market Report and Directory–Edition 2017, a 1,100-page document that provides an exhaustive description and analysis of more than 390 products, including over 140 radiopharmaceuticals under clinical development, with a comprehensive profile of 193 companies and institutions active in the radiopharmaceuticals industry.
Detailed table of contents and sample pages available upon request a peg@medraysintell.com
MEDraysintell estimates that the global market for nuclear medicine reached US$ 4.5…
MEDraysintell to showcase its reports at SNNMI in Denver
MEDraysintell will display its series of market reports and directories with over 1,900 pages of unrivaled intelligence covering Nuclear Medicine, Cyclotrons, Brachytherapy and Proton Therapy, during the SNMMI – Society of Nuclear Medicine and Molecular Imaging– congress (Denver, CO, USA, June 10-14, 2017), www.snmmi.org/am2017
MEDraysintell is gratefully hosted by the company ANMI and visitors are welcome at booth #957.
MEDraysintell estimates the global market for nuclear medicine (radiopharmaceuticals) has reached US$ 4.5…
Nuclear Medicine, Proton Therapy, Brachytherapy reports and directories
Nuclear medicine, proton therapy and brachytherapy are niche markets which together represents less than 0.1% of the global health expenditures but should grow three times faster. While the global expenses on health reached some US$ 7,500 billion in 2016 and should growth by 3-4% a year to 2030, the nuclear medicine, proton therapy and brachytherapy markets reached over US$ 6 billion in 2016 and are expected to growth more than…
MEDraysintell releases its Proton Therapy Market Essentials report 2017
MEDraysintell publishes its new “Proton Therapy Market Essentials” report providing key facts and figures on Proton Therapy to advice non-industry insiders on the potential for investments, market development, merger and acquisitions (M&A) existing in this healthcare technology.
This “Proton Therapy Market Essentials” report will be a real asset for institutions looking to implement a new proton therapy center and for the financial community (investors, investment bankers and M&A professionals) to support…
MEDraysintell releases its first Nuclear Medicine Market Essentials report
MEDraysintell publishes its new “Nuclear Medicine Market Essentials” report providing key facts and figures on Nuclear Medicine to advice non-industry insiders on the potential for investments, merger and acquisitions (M&A), technology and market development existing in this healthcare technology.
This “Nuclear Medicine Market Essentials” report will be a real asset for the healthcare industry or for the financial community (investors, investment bankers and M&A professionals) to support their audit and to…
